{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T16:53:01Z","timestamp":1790009581443,"version":"4.0.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T00:00:00Z","timestamp":1704153600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T00:00:00Z","timestamp":1704153600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Disseminated intravascular coagulation (DIC) occurs in 30\u201350% of septic patients and contributes to high mortality in the intensive care unit (ICU). However, there are few proven interventions for coagulation disorder management in sepsis. Experimental and clinical data have demonstrated that sepsis could benefit from unfractionated heparin (UFH) treatment. To date, there are no large multicenter trials to determine the safety and efficacy of UFH in septic patients with suspected DIC.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A multicenter, double-blinded, placebo-controlled randomized trial is designed to recruit 600 patients who met sepsis 3.0 criteria and suspected DIC. Participants will be randomized (1:1) to receive UFH or saline via continuous intravenous administration for 7 days within 6 h of enrolment. The primary outcome is ICU mortality. The secondary outcome includes 28-day all-cause mortality, the improvement of Sequential Organ Failure Assessment scores, and the incidence of major hemorrhage. Investigators, participants, and statisticians will be blinded to the allocation.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>The HepSIC trial is to evaluate the efficacy and safety of UFH on sepsis-related DIC across different areas of China. The small dosage of UFH administration would offer a new potential approach for treating sepsis-related coagulation disorders.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Ethics and dissemination<\/jats:title>\n                <jats:p>Ethical approval was granted by all the ethics committees of 20 participant centers. Results will be disseminated via peer-reviewed publications and presented at conferences.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>ClinicalTrials.gov NCT02654561. Registered on 13 January 2016.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13063-023-07853-5","type":"journal-article","created":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T11:02:24Z","timestamp":1704193344000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Efficacy and safety of heparin for sepsis-induced disseminated intravascular coagulation (HepSIC): study protocol for a multicenter randomized controlled trial"],"prefix":"10.1186","volume":"25","author":[{"given":"Yini","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renyu","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingjian","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1714-9800","authenticated-orcid":false,"given":"Xiaochun","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,2]]},"reference":[{"issue":"8","key":"7853_CR1","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1001\/jama.2016.0287","volume":"315","author":"M Singer","year":"2016","unstructured":"Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). Jama. 2016;315(8):801\u201310.","journal-title":"Jama."},{"issue":"10219","key":"7853_CR2","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/S0140-6736(19)32989-7","volume":"395","author":"KE Rudd","year":"2020","unstructured":"Rudd KE, Johnson SC, Agesa KM, Shackelford KA, Tsoi D, Kievlan DR, et al. Global, regional, and national sepsis incidence and mortality, 1990-2017: analysis for the Global Burden of Disease Study. Lancet. 2020;395(10219):200\u201311.","journal-title":"Lancet."},{"issue":"2","key":"7853_CR3","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1097\/01.CCM.0000153520.31562.48","volume":"33","author":"JF Dhainaut","year":"2005","unstructured":"Dhainaut JF, Shorr AF, Macias WL, Kollef MJ, Levi M, Reinhart K, et al. Dynamic evolution of coagulopathy in the first day of severe sepsis: relationship with mortality and organ failure. Crit Care Med. 2005;33(2):341\u20138.","journal-title":"Crit Care Med."},{"key":"7853_CR4","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.thromres.2016.11.007","volume":"149","author":"M Levi","year":"2017","unstructured":"Levi M, van der Poll T. Coagulation and sepsis. Thromb Res. 2017;149:38\u201344.","journal-title":"Thromb Res."},{"issue":"2","key":"7853_CR5","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/cc1825","volume":"7","author":"M Riewald","year":"2003","unstructured":"Riewald M, Ruf W. Science review: role of coagulation protease cascades in sepsis. Crit Care. 2003;7(2):123\u20139.","journal-title":"Crit Care."},{"issue":"1","key":"7853_CR6","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/cc1854","volume":"7","author":"SM Opal","year":"2003","unstructured":"Opal SM, Esmon CT. Bench-to-bedside review: functional relationships between coagulation and the innate immune response and their respective roles in the pathogenesis of sepsis. Crit Care. 2003;7(1):23\u201338.","journal-title":"Crit Care."},{"issue":"6","key":"7853_CR7","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1056\/NEJM200108093450603","volume":"345","author":"SN Faust","year":"2001","unstructured":"Faust SN, Levin M, Harrison OB, Goldin RD, Lockhart MS, Kondaveeti S, et al. Dysfunction of endothelial protein C activation in severe meningococcal sepsis. N Engl J Med. 2001;345(6):408\u201316.","journal-title":"N Engl J Med."},{"issue":"3","key":"7853_CR8","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1055\/s-0038-1648137","volume":"65","author":"J Philippe","year":"1991","unstructured":"Philippe J, Offner F, Declerck PJ, Leroux- Roels G, Vogelaers D, Baele G, et al. Fibrinolysis and coagulation in patients with infectious disease and sepsis. Thrombosis and Haemostasis. 1991;65(3):291\u20135.","journal-title":"Thrombosis and Haemostasis."},{"issue":"10","key":"7853_CR9","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJM200103083441001","volume":"344","author":"GR Bernard","year":"2001","unstructured":"Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001;344(10):699\u2013709.","journal-title":"N Engl J Med."},{"issue":"15","key":"7853_CR10","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1001\/jama.286.15.1869","volume":"286","author":"BL Warren","year":"2001","unstructured":"Warren BL, Eid A, Singer P, Pillay SS, Carl P, Novak I, et al. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. Jama. 2001;286(15):1869\u201378.","journal-title":"Jama."},{"issue":"9","key":"7853_CR11","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1097\/CCM.0b013e31828e9b03","volume":"41","author":"JL Vincent","year":"2013","unstructured":"Vincent JL, Ramesh MK, Ernest D, LaRosa SP, Pachl J, Aikawa N, et al. A randomized, double-blind, placebo-controlled, Phase 2b study to evaluate the safety and efficacy of recombinant human soluble thrombomodulin, ART-123, in patients with sepsis and suspected disseminated intravascular coagulation. Crit Care Med. 2013;41(9):2069\u201379.","journal-title":"Crit Care Med."},{"issue":"3","key":"7853_CR12","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1111\/jth.13230","volume":"14","author":"Y Umemura","year":"2016","unstructured":"Umemura Y, Yamakawa K, Ogura H, Yuhara H, Fujimi S. Efficacy and safety of anticoagulant therapy in three specific populations with sepsis: a meta-analysis of randomized controlled trials. J Thromb Haemost. 2016;14(3):518\u201330.","journal-title":"J Thromb Haemost."},{"issue":"20","key":"7853_CR13","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1001\/jama.2019.5358","volume":"321","author":"JL Vincent","year":"2019","unstructured":"Vincent JL, Francois B, Zabolotskikh I, Daga MK, Lascarrou JB, Kirov MY, et al. Effect of a Recombinant Human Soluble Thrombomodulin on Mortality in Patients With Sepsis-Associated Coagulopathy The SCARLET Randomized Clinical Trial. Jama. 2019;321(20):1993\u20132002.","journal-title":"Jama."},{"issue":"8","key":"7853_CR14","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1097\/CCM.0000000000004426","volume":"48","author":"M Levi","year":"2020","unstructured":"Levi M, Vincent JL, Tanaka K, Radford AH, Kayanoki T, Fineberg DA, et al. Effect of a Recombinant Human Soluble Thrombomodulin on Baseline Coagulation Biomarker Levels and Mortality Outcome in Patients With Sepsis-Associated Coagulopathy. Crit Care Med. 2020;48(8):1140\u20137.","journal-title":"Crit Care Med."},{"issue":"6","key":"7853_CR15","doi-asserted-by":"publisher","first-page":"e160","DOI":"10.1016\/j.thromres.2011.07.044","volume":"128","author":"R Ding","year":"2011","unstructured":"Ding R, Zhao D, Guo R, Zhang Z, Ma X. Treatment with unfractionated heparin attenuates coagulation and inflammation in endotoxemic mice. Thromb Res. 2011;128(6):e160\u20135.","journal-title":"Thromb Res."},{"issue":"5","key":"7853_CR16","doi-asserted-by":"publisher","first-page":"e223","DOI":"10.1016\/j.thromres.2012.03.003","volume":"129","author":"X Li","year":"2012","unstructured":"Li X, Zheng Z, Mao Y, Ma X. Unfractionated heparin promotes LPS-induced endothelial barrier dysfunction: a preliminary study on the roles of angiopoietin\/Tie2 axis. Thromb Res. 2012;129(5):e223\u20138.","journal-title":"Thromb Res."},{"issue":"7","key":"7853_CR17","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1182\/blood-2013-07-514984","volume":"123","author":"KCAA Wildhagen","year":"2014","unstructured":"Wildhagen KCAA, Garcia de Frutos P, Reutelingsperger CP, Schrijver R, Areste C, Orega-Gomez A, et al. Nonanticoagulant heparin prevents histone-mediated cytotoxicity in vitro and improves survival in sepsis. Blood. 2014;123(7):1098\u2013101.","journal-title":"Blood."},{"issue":"5","key":"7853_CR18","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1186\/s13054-014-0563-4","volume":"18","author":"C Wang","year":"2014","unstructured":"Wang C, Chi C, Guo L, Wang X, Guo L, Sun J, et al. Heparin therapy reduces 28-day mortality in adult severe sepsis patients: a systematic review and meta-analysis. Crit Care. 2014;18(5):563.","journal-title":"Crit Care."},{"issue":"3","key":"7853_CR19","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1097\/CCM.0000000000000763","volume":"43","author":"R Zarychanski","year":"2015","unstructured":"Zarychanski R, Abou-Setta AM, Kanji S, Turgeon AF, Kumar A, Houston DS, et al. The efficacy and safety of heparin in patients with sepsis: a systematic review and metaanalysis. Crit Care Med. 2015;43(3):511\u20138.","journal-title":"Crit Care Med."},{"issue":"11","key":"7853_CR20","doi-asserted-by":"publisher","first-page":"2973","DOI":"10.1097\/CCM.0b013e31818b8c6b","volume":"36","author":"R Zarychanski","year":"2008","unstructured":"Zarychanski R, Doucette S, Fergusson D, Roberts D, Houston DS, Sharma S, et al. Early intravenous unfractionated heparin and mortality in septic shock. Crit Care Med. 2008;36(11):2973\u20139.","journal-title":"Crit Care Med."},{"issue":"4","key":"7853_CR21","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1097\/CCM.0b013e31819c06bc","volume":"37","author":"F Jaimes","year":"2009","unstructured":"Jaimes F, De La Rosa G, Morales C, Fortich F, Arango C, Aguirre D, et al. Unfractioned heparin for treatment of sepsis: A randomized clinical trial (The HETRASE Study). Crit Care Med. 2009;37(4):1185\u201396.","journal-title":"Crit Care Med."},{"issue":"2","key":"7853_CR22","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.jcrc.2009.12.006","volume":"25","author":"MA Crowther","year":"2010","unstructured":"Crowther MA, Cook DJ, Albert M, Williamson D, Meade M, Granton J, et al. The 4Ts scoring system for heparin-induced thrombocytopenia in medical-surgical intensive care unit patients. J Crit Care. 2010;25(2):287\u201393.","journal-title":"J Crit Care."},{"key":"7853_CR23","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1055\/s-0039-1694995","volume":"46","author":"T Iba","year":"2020","unstructured":"Iba T, Levi M, Levy JH. Sepsis-Induced Coagulopathy and Disseminated Intravascular Coagulation. Semin Thromb Hemost. 2020;46:89\u201395.","journal-title":"Semin Thromb Hemost."},{"key":"7853_CR24","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.3390\/jcm8111869","volume":"8","author":"S Murao","year":"2019","unstructured":"Murao S, Yamakawa K. A Systematic Summary of Systematic Reviews on Anticoagulant Therapy in Sepsis. J Clin Med. 2019;8:1869.","journal-title":"J Clin Med."},{"issue":"3","key":"7853_CR25","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1111\/bjh.14885","volume":"179","author":"X Li","year":"2017","unstructured":"Li X, Ma X. The role of heparin in sepsis: much more than just an anticoagulant. Br J Haematol. 2017;179(3):389\u201398.","journal-title":"Br J Haematol."},{"issue":"5","key":"7853_CR26","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1055\/s-0028-1092876","volume":"34","author":"M Levi","year":"2008","unstructured":"Levi M, van der Poll T. The role of natural anticoagulants in the pathogenesis and management of systemic activation of coagulation and inflammation in critically ill patients. Semin Thromb Hemost. 2008;34(5):459\u201368.","journal-title":"Semin Thromb Hemost."},{"issue":"2","key":"7853_CR27","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1001\/jama.290.2.238","volume":"290","author":"E Abraham","year":"2003","unstructured":"Abraham E, Reinhart K, Opal S, Demeyer I, Doig C, Rodriguez AL, et al. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. Jama. 2003;290(2):238\u201347.","journal-title":"Jama."},{"issue":"5","key":"7853_CR28","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.cjtee.2023.04.006","volume":"26","author":"JY Guo","year":"2023","unstructured":"Guo JY, Lin HY. Why anticogulant sudies on sepsis fail frequently---start with SCARLET. Chin J Traumatol. 2023;26(5):297\u2013302.","journal-title":"Chin J Traumatol."},{"issue":"9734","key":"7853_CR29","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/S0140-6736(10)60835-5","volume":"376","author":"H Shakur","year":"2010","unstructured":"CRASH-2 trial collaborators, Shakur H, Roberts I, Bautista R, Caballero J, Coats T, et al. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet. 2010;376(9734):23\u201332.","journal-title":"Lancet."},{"issue":"6","key":"7853_CR30","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1007\/s10753-013-9656-5","volume":"36","author":"X Li","year":"2013","unstructured":"Li X, Li Z, Zheng Z, Liu Y, Ma X. Unfractionated Heparin Ameliorates Lipopolysaccharide- Induced Lung Inflammation by Downregulating Nuclear Factor-\u03baB Signaling Pathway. Inflammation. 2013;36(6):1201\u20138.","journal-title":"Inflammation."},{"issue":"5","key":"7853_CR31","first-page":"4903","volume":"8","author":"S Chen","year":"2015","unstructured":"Chen S, Zhang X, Sun Y, Hu Z, Lu S, Ma X. Unfractionated heparin attenuates intestinal injury in mouse model of sepsis by inhibiting heparanase. Int J Clin Exp Pathol. 2015;8(5):4903\u201312.","journal-title":"Int J Clin Exp Pathol."},{"issue":"2","key":"7853_CR32","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1111\/aas.12418","volume":"59","author":"S Yini","year":"2015","unstructured":"Yini S, Heng Z, Xin A, Xiaochun M. Effect of unfractionated heparin on endothelial glycocalyx in a septic shock model. Acta Anaesthesiol Scand. 2015;59(2):160\u20139.","journal-title":"Acta Anaesthesiol Scand."},{"issue":"1","key":"7853_CR33","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1186\/s12931-018-0925-6","volume":"19","author":"S Mu","year":"2018","unstructured":"Mu S, Liu Y, Jiang J, Ding R, Li X, Li X, et al. Unfractionated heparin ameliorates pulmonary microvascular endothelial barrier dysfunction via microtubule stabilization in acute lung injury. Respir Res. 2018;19(1):220.","journal-title":"Respir Res."},{"issue":"14","key":"7853_CR34","first-page":"1087","volume":"135","author":"X Yang","year":"2020","unstructured":"Yang X, Cheng X, Tang Y, Qiu X, Wang Z, Fu G, et al. The role of type 1 interferons in coagulation induced by gram-negative bacteria. Blood. 2020;135(14):1087\u2013100.","journal-title":"Blood."},{"key":"7853_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.immuni.2021.01.007","volume":"54","author":"Y Tang","year":"2021","unstructured":"Tang Y, Wang X, Li Z, He Z, Yang X, Cheng X, et al. Heparin prevents caspase-11-dependent septic lethality independent of anticoagulant properties. Immunity. 2021;54:1\u201314.","journal-title":"Immunity."}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-023-07853-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-023-07853-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-023-07853-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T11:04:43Z","timestamp":1704193483000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-023-07853-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,2]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["7853"],"URL":"https:\/\/doi.org\/10.1186\/s13063-023-07853-5","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,2]]},"assertion":[{"value":"15 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the Research and Ethics Committee of the First Affiliated Hospital of China Medical University ([2015]2015-113-2, Shenyang, China). Ethical approval was granted by all the ethics committees of 20 participant centers. Written informed consent to participate will obtained from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4"}}